Industry: Health care Region: France Transaction price: US$ 1 million Transaction method: equity investment
Project introduction:
A French biotechnology company, founded in 2018, focuses on providing high-level in vitro testing services to evaluate the safety and efficacy of cosmetics, drugs and medical devices. The company is committed to replacing animal experiments and promoting the wide application of in vitro experiments in dermatology, lung diseases, drug metabolism and other fields. Enterprises use advanced human cell models (including skin reconstruction, lung slice PCLS, 2D/3D cell culture, etc.) and combine international standards such as OECD and SCCS to provide customized testing solutions covering skin absorption, inflammatory response, sensitization, phototoxicity, anti-aging and other aspects.
Business introduction:
1. In vitro safety test
Under the premise of not using animals, whether the product is safe, such as skin absorption, irritation, phototoxicity, skin irritation, sensitization, etc., can be detected by "artificial skin" or human cell model.
2. In vitro efficacy test
Test the efficacy of the product, such as whitening, anti-aging, moisturizing and repairing effects, the influence on inflammation or melanin, and whether the drug can penetrate the skin or act on lung and liver tissues.
3. Consultation and training
It can help enterprises to design scientific test plans, interpret test results, and train R&D personnel to use alternative animal experiments.
Cooperation mode:
Looking for partners who need in vitro testing services in the fields of cosmetics, pharmaceuticals and medical devices.